FDA Guidance Finalizes Generic Drug Makers' Process for Communicating with the Agency

October 2, 2015

This week FDA finalized its draft guidance on Controlled Correspondence Related to Generic Drug Development. Although all submitted comments were considered, FDA’s revised the draft to “provide clarifying and explanatory information that will assist human generic drug manufacturers and related industry as they submit controlled correspondence to FDA.” The following additions were included in the final guidance:

  • A Description of a process to submit information to update the Agency’s Inactive Ingredient Database.
  • A Description of enhanced communication to requestors regarding the status of their controlled correspondence.

Additionally, the guidance excluded three types of inquiries that will continue to be treated differently from other generic drug development inquiries even though they technically fall under the definition of controlled correspondence. These include: “(1) requests for recommendations on the appropriate design of BE studies for a specific drug product (BE guidance requests); (2) requests for review of BE clinical protocols (clinical protocol requests); and (3) requests for meetings to discuss generic drug development prior to ANDA submission (pre-ANDA meeting requests).”

Have you developed, or are you in the process of developing, a generic product? Need assistance submitting correspondence and information requests to FDA? We can help you through the entire process, from the initial communication to receiving FDA approval for your product. To learn more about our services and how we can help you, please contact us.

TAGS:

March 6, 2017

2016 was Record-Setting Year for Generic Drug Approvals, Reports FDA

In a recent post on the FDA Voice blog, the Agency reported that its generic drug program hit record highs in 2016. In the blog post, Kathleen “Cook” Uhl, M.D., Director of FDA’s Office of Generic...

May 4, 2016

FDA Guidelines for Post-Approval CMC Changes, Part Two: Contents of Comparability Protocol Submissions

Additional information on FDA's draft guidance is available in our preceding FDA News article, entitled "FDA Guidelines for Post-Approval CMC Changes, Part One: Overview of the Updated Draft...

August 29, 2016

FDA Issues Guidance Regarding the Agency’s Refuse to Receive Policy for Certain Abbreviated New Drug Applications

On Wednesday, August 24th FDA released a final guidance document, entitled “Abbreviated New Drug Application Submissions – Refuse to Receive for Lack of Justification of Impurity Limits,” which...